PM's Science Council To Set Direction For Science
Prime Minister
Prime Minister Christopher Luxon has today announced the new Prime Minister's Chief Science Advisor, and the members of the Prime Minister's Science and Technology Advisory Council.
'We have world-class scientists in our universities and research institutes, but they're working in a system held back by outdated settings. To unlock the full potential of science and technology, we need a sharper focus on commercialisation, better access to global investment, and clearer priorities at home,' Mr Luxon says.
'This Council is a new initiative to get clear, independent advice to ensure our investments in science and technology are delivering real outcomes for New Zealanders.
'The Council will provide advice on long-term priorities for government-funded science and innovation. They will help identify areas of focus that will have the greatest benefit for Kiwis and our economy.
'I also expect them to provide bold and courageous advice about those areas that aren't delivering value for New Zealanders and may need to be deprioritised. It's about making sure we are investing in what will have the greatest impact for New Zealanders.'
Members of the Council bring a strong mix of scientific, commercial and strategic expertise. They include:
Sir Peter Gluckman
Craig Piggott
Professor Merryn Tawhai
Komal Mistry-Mehta
Malcolm Johns
Dr John Roche
'I am also pleased to announce that Dr John Roche has been appointed as the Prime Minister's Chief Science Advisor. In this role, John will support robust decision making by providing high quality, independent scientific advice. John, in his capacity as my science advisor, will also be a member of the council.'
Minister for Science, Innovation and Technology, Hon Dr Shane Reti, will chair the Council, with Dr John Roche as deputy chair.
'These are highly capable individuals who understand both the science and the economic imperatives. They are prepared to make the bold calls needed to ensure the system is future-focused, outcome-driven and aligned with our economic goals,' Mr Luxon says.
'A strong, well-directed science and innovation sector is critical to lifting productivity, creating high-value jobs and supporting a more resilient and competitive economy.'
The Council will provide its first formal advice to the Prime Minister and Minister Reti later this year.
Biographies of Council members:
Sir Peter Gluckman
Professor Sir Peter Gluckman ONZ KNZM FRSNZ FMedSci FRS trained as a paediatrician and biomedical scientist. He is Director of Koi Tu- Centre for Informed Futures and holds a Distinguished University Professorship at the University of Auckland. He is currently the chair of the Science System Advisory Group. Sir Peter is President of the International Science Council (ISC, 2021-2026). From 2014-2021 he was the inaugural Chair of the International Network of Government Science Advice (INGSA), and from 2009-2018 he was the first Chief Science Advisor to the Prime Minister of New Zealand. He was also Science Envoy for the New Zealand Ministry of Foreign Affairs and Trade and coordinated the secretariat of the Small Advanced Economies Initiative. He has written and spoken extensively on science-policy and science-diplomacy and science-society interactions. He has received the highest scientific and civilian honours in New Zealand and numerous international scientific awards.
Craig Piggott
Craig Piggott is the founder of Halter. The company's solar-powered collar for dairy and beef cows, pairs with an app for farmers and allows cows to respond to guidance cues, enabling virtual herding and fencing while monitoring health 24/7. This innovation helps farmers increase milk and protein production propelling the company to become one of New Zealand's fastest-growing businesses with a thriving international customer base. Craig brings experience in innovation, agriculture and business.
Merryn Tawhai
Merryn Tawhai graduated from the University of Auckland with a PhD in Engineering Science in 2001. She leads a research programme at the Auckland Bioengineering Institute (ABI) in applied computational physiology of the respiratory system. Merryn is the Director of the ABI and sits on the Board of Directors for Cure Kids Ventures and the Virtual Physiological Human Institute. She was ABI's Deputy Director for 10 years, Director of the Medical Technologies Centre of Research Excellence (MedTech CoRE), and an independent Director for Izon Science. Merryn was awarded the 2016 MacDiarmid Medal by the Royal Society of New Zealand (RSNZ) Te Apārangi, is a Fellow of the RSNZ, a Fellow of IAMBE and AIMBE, and an elected member of the Fleischner Society.
Komal Mistry-Mehta
Komal is Chief Innovation & Brand Officer at Fonterra and Managing Director of the Ki Tua Fund, Fonterra's corporate venture capital arm. She leads global innovation, research and development, digital, brand and marketing functions for New Zealand's largest company. Prior to joining the Fonterra Executive Team, Komal led Fonterra's global health and nutrition business based in Singapore. With experience across Asia, the America's and Europe, she has led major transformations in sales, innovation, digital enablement and technology. Komal was named New Zealand's Young Executive of the Year in 2017 and serves on several international boards. Komal has completed the Executive Program at Stanford University School of Business and holds Bachelor of Laws and Bachelor of Management degrees from the University of Waikato. She is a Barrister and Solicitor of the High Court of New Zealand as well as a member of the New Zealand Institute of Chartered Accountants.
Malcolm Johns
Malcolm is the Chief Executive of Genesis Energy. Previously he was the Chief Executive of InterCity Group and held several governance roles within New Zealand's transport, infrastructure and tourism sectors. He is Convenor of the Climate Leaders Coalition and served as Chair of the APEC Business Advisory Council leading the regional trade policy task force for climate change. Malcolm has extensive business acumen and understanding of Government systems
John Roche
John was appointed MPI's Chief Science Adviser in June 2018 to provide an independent science perspective. He leads MPI's Science Forum, chairs the Science Governance Group at MPI and the independent Mycoplasma bovis Strategic Science Advisory Group. John is also a member of the Prime Minister's Chief Science Adviser's forum and is an adjunct professor in University of Auckland's School of Biological Sciences. John was previously DairyNZ's Principal Scientist for Animal Science. He has held science appointments in Ireland and Australia. He is also Managing Director of Down to Earth Advice Ltd. Widely published and a regular contributor to international science and farming conferences, John has an Honours degree in Agricultural Science, a Masters in Farm Systems and Pasture Management, and a PhD in Animal Nutrition.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scoop
33 minutes ago
- Scoop
OCR Cut Welcome For Some While Govt Leaves Many Behind
Poverty and homelessness continue to grow because of this Government's decisions, despite the Reserve Bank's move to lower the Official Cash Rate (OCR). 'The Reserve Bank's decision to lower interest rates today will be welcome news for some but won't help the thousands this Government has pushed into homelessness and poverty,' says Green Party co-leader and spokesperson for Finance Chlöe Swarbrick. 'Monetary policy is a blunt instrument. It is fiscal policy - that is, the Government's choices on tax and spend - which dictates who wins and who loses in our economy. 'While the OCR cut will provide some relief for those with a mortgage, the number of New Zealanders left out in the cold continues to grow under Luxon's decisions. Reports out today show families being forced to choose between unsafe boarding houses, or living on the street. 'Cuts to the OCR do not end poverty or homelessness, nor arrest growing inequality. The Government knows it can take action to address these problems, but is instead choosing to make them worse. 'While this Government tells people they're making the 'hard choices' to push more kids into poverty and increase emissions, the Greens will continue to fight for an Aotearoa where everyone thrives and nobody is left behind,' says Chlöe Swarbrick.
Scoop
2 hours ago
- Scoop
Cancer, Measles And Allergic Disease Research Funded In Latest HRC Grants Round
The Malaghan Institute has been awarded three Health Research Council grants, totalling $7.4M over five years, to improve cancer immunotherapies, protect vulnerable populations from measles outbreaks and investigate new therapeutic targets for eczema. Director Professor Kjesten Wiig says receiving three major grants from the Health Research Council at a time of heightened funding constraints is significant and recognises the calibre and relevance of the Malaghan Institute's science. 'These investments not only reflect confidence in the Malaghan's research across cancer, allergic and infectious diseases, but also the real-world impact of our work on the health of New Zealanders.' Faster CARs: Overcoming exhaustion to enhance cancer immunotherapies Building on the Malaghan Institute's ground-breaking CAR T-cell programme, the Perret team in the Weinkove Laboratory has recieved a $1.2 million project grant over three years to improve on this life-saving treatment. 'In Aotearoa's first CAR T-cell trial, our novel CAR T-cell therapy has shown promising safety and efficacy in people with relapsed lymphomas,' says Dr Rachel Perret. 'However, a known limitation of CAR T-cell therapies is that in some cases, cancers fail to respond, or relapse. This may be due to exhaustion of CAR T-cells during manufacture or inside the patient, due to a immunosuppressive environment around the tumour.' Cells, like people, can become exhausted if overworked or overstimulated, becoming less and less able to perform. However, unlike people, CAR T-cells can be tweaked to block the genes that signal this exhaustion, allowing them to continue fighting cancer for longer – which should also improve patient outcomes. 'This project will re-engineer CAR T-cells to silence genes linked to exhaustion and re-develop CAR T-cell manufacturing processes to enhance CAR T- cell fitness and shorten manufacturing times,' says Dr Perret. 'We expect the results to be applicable to many cancer types, and to be readily translated for the benefit of New Zealanders within our CAR T-cell clinical trial programme.' Providing equal protection for everyone against measles Herd immunity is how we as a population protect those who are immunocompromised or otherwise unable to get vaccinated (such as very young infants) against potentially life-threatening viruses like measles. When enough of the population are vaccinated (over 95% in the case of measles), this herd immunity effectively prevents viruses from spreading to our most vulnerable whānau. 'While the current measles, mumps and rubella (MMR) vaccine is highly effective at protecting vaccinated individuals against these viruses, current vaccination rates are not high enough to provide this essential herd immunity to protect those who cannot be vaccinated,' says paediatric immunologist Dr Kuang Hsiao from Waipapa Taumata Rau, University of Auckland, who is part of the research team. The MMR vaccine cannot be used in people with severely impaired immune systems and is not recommended in pregnant people. Also, MMR is less effective in infants, so is not routinely recommended before 12 months of age. In addition, Māori and Pacific communities are overrepresented among these vulnerable groups. For these populations, alternate protective options are required to prevent a measles outbreak. 'Evidence has shown that mRNA-based vaccines can be effective in these vulnerable individuals,' says the Malaghan's Professor Ian Hermans. 'With an international team involving clinicians, immunologists and Māori and Pacific researchers, we will develop an mRNA-based measles vaccine to give to vulnerable individuals in the event of an outbreak.' The research has been awarded an HRC Programme Grant, worth $5M over five years, and will bring together multiple organisations including the Malaghan, representing diverse areas of expertise and combining both fundamental research and public health. 'As part of this work, we will explore with Māori and Pacific communities' perceptions and beliefs about mRNA-based vaccines to support equitable access to the vaccine,' says Dr Hermans. Investigating novel treatment targets for atopic dermatitis Atopic dermatitis, or eczema, is a chronic skin allergic disease that affects a significant proportion of New Zealand's population. The disease can have a significant negative impact on a person's livelihood with symptoms varying from persistent itchiness, redness, dryness and inflammation. Current treatment options are largely immunosuppressants such as corticosteroids, which can cause side effects. While these treatments can help manage symptoms there are currently no effective therapies to prevent the disease from developing and relapsing. At the cellular level, one hallmark of atopic dermatitis is the chronic infiltration and persistence of immune cells called tissue resident memory T-cells. Normally, these cells are vital for protecting the skin from invading pathogens, but for individuals with atopic dermatitis these cells also contribute to the disease by promoting recurring inflammation even after the allergen has been cleared from the skin. The project, which has been awarded $1.2 million over three years, will be led by Dr Sotaro Ochiai, a Senior Research Fellow in the Ronchese Laboratory. The team will focus on better understanding these tissue resident memory T-cells identifying key genes and biological pathways that are essential for the establishment and maintenance of these cells in the skin. 'By understanding these mechanisms, we aim to identify new therapeutic targets to disrupt tissue resident memory T-cell survival or function and improve quality of life for those affected by this persistent and distressing condition,' says Dr Ochiai.
Techday NZ
4 hours ago
- Techday NZ
Seventy-two percent of New Zealanders say brands break promises
Nearly three-quarters of New Zealand consumers believe companies are not living up to the promises they make, according to a new study from Accenture Song. The Brand Experience Gap study, now in its second year, surveyed 1,527 New Zealanders and reviewed 65 brands across six sectors. The findings indicate that 72% of respondents feel brands are failing to deliver on their commitments, marking a slight increase from the previous year's figure of 71%. Financial services providers were rated as the best performing sector, with an experience gap of 63%, meaning that 63% of customers do not think their primary provider fulfils its promises. On the other end of the spectrum, media and entertainment firms - including content streaming services - had the largest experience gap at 79%. Consumer expectations Consumers identified specific areas where brands are falling short. In the financial services sector, 33% of respondents cited the need for more reasonable fees and interest rates as a key area for improvement. For media and entertainment, 81% wanted more control over how they manage and customise content, while 78% said content needs to be refreshed more regularly to avoid becoming repetitive or stale. Across all sectors, the three most significant shortfalls were consumers not feeling valued or recognised by brands (79%), perceptions that brands are not making a positive social contribution (78%), and a lack of up-to-date technology to make interactions more convenient (77%). Other industries assessed The study also measured the experience gap for other sectors in New Zealand. General insurance brands were found to have a gap of 71%, telecommunications providers 72%, utilities 68%, and travel and tourism 76%. With the experience gap persisting across most industries, Storm Day, NZ Lead at Accenture Song, commented on the growing expectations of New Zealand consumers: "Customers are demanding more from the brands they deal with, and rightly so. In an increasingly complex business environment, companies simply can't afford to promise what they can't deliver. Again in 2025, we're seeing a stubbornly high experience gap among brands in New Zealand. But this gap comes with an opportunity, as closing it is one of the best ways to build long-term customer trust." "The key is to treat customer experience as a purpose-led growth driver, not just a budget line item. Sectors like financial services are holding steady because they've invested in owning the customer experience, along with the systems and strategies to support it." "It's also important to remember that your brand doesn't exist in a vacuum. You might be closing gaps, but if your competitors are closing them faster, people notice that. Customers' experiences are framed by all the organisations they deal with, not just those in your sector. That's crucial, because customers don't always complain – they simply don't come back. They disappear silently, often to your competitors." "By harnessing smart technologies like generative AI to deliver genuine organisational purpose, we're on a mission to turn intent into action – and close the gap," said Day. Research methodology The Brand Experience Gap study measures the difference between what brands publicly promise and what their actual customers report experiencing. Respondents were asked about universal brand values - such as simplicity, ease of dealing with a company, and feeling valued - and sector-specific aspects like fraud protection in financial services. Results reflect the proportion of customers in each sector who feel there is a gap between a company's stated intentions and delivered outcomes. The report highlights a consistent challenge for New Zealand brands across industries: the need to improve how customers feel recognised, how technology is leveraged, and how brands contribute to society in order to rebuild trust and loyalty. Follow us on: Share on:
